,
Sunderland, Kelly M.
Beaton, Derek
Fraser, Julia
Kwan, Donna
McLaughlin, Paula M.
Montero-Odasso, Manuel
Peltsch, Alicia J.
Pieruccini-Faria, Frederico
Sahlas, Demetrios J.
Swartz, Richard H.
Strother, Stephen C.
Binns, Malcolm A.
Funding for this research was provided by:
Ontario Brain Institute (NA)
Canadian Institutes of Health Research (MOP 201403)
Canadian Institutes of Health Research (PJT 153100)
Ontario ministry of research and innovation (ER11-08-101)
Canadian Consortium in Neurodegeneration in Aging (CAN 137794)
Department of Medicine Program of Experimental Medicine Research Award (768915)
Western University (NA)
CIHR Investigator Award (NA)
Sunnybrook Research Institute (NA)
University of Toronto (NA)
Heart and Stroke Foundation of Canada (NA)
Article History
Received: 23 November 2018
Accepted: 22 April 2019
First Online: 15 May 2019
Ethics approval and consent to participate
: The Ontario Neurodegenerative Disease Research Initiative has been reviewed and approved by the Baycrest Research Ethics Board. The Baycrest Research Ethics Board operates in compliance with the Tri-Council Policy Statement, ICH/GCP Guidelines and Part C, Division 5 of the Food and Drug Regulations of Health Canada. All ONDRI participants provided written and informed consent.
: Not applicable.
: SS is the Chief Scientific Officer of ADMdx, a medical diagnostics company specializing in neuroimaging of neurodegenerative disorders.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.